Treatment with receptor-tyrosine kinase inhibitors (TKIs), particular EGFR targets, such as Gefitinib, Erlotinib, and Afatinib, have been explored to treat advanced lung adenocarcinoma during the past decades and show distinct treatment advantages over cytotoxic therapy at progression-free and overall survival2. The gene discussed is NTRK1; the disease is lung adenocarcinoma.